Cargando…

Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All‐Cause Mortality in Clinical Trials of Time‐Constrained Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention

BACKGROUND: The net clinical benefit of dual antiplatelet therapy (DAPT) reflects the paradoxical effects of an increased risk of bleeding and a reduced risk of major adverse cardiovascular events. A time‐constrained approach to DAPT has been recently investigated in 5 multicenter trials including G...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClure, John D., Ramsay, Jennifer C., Berry, Colin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660822/ https://www.ncbi.nlm.nih.gov/pubmed/32779497 http://dx.doi.org/10.1161/JAHA.120.017109

Ejemplares similares

Case‐fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta‐analysis
por: Tritschler, Tobias, et al.
Publicado: (2022)

Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy
por: Egholm, Gro, et al.
Publicado: (2016)

Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation
por: Staudacher, Dawid L., et al.
Publicado: (2016)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
por: Ramesh, S., et al.
Publicado: (2020)

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events
por: Ikebe, So, et al.
Publicado: (2023)

Incorporation of Laboratory Test Biomarkers Into Dual Antiplatelet Therapy Score Improves Prediction of Ischemic and Bleeding Events in Post-percutaneous Coronary Intervention Patients
por: Sun, Chengming, et al.
Publicado: (2022)

An up-dated meta-analysis of major adverse cardiac events on triple versus dual antiplatelet therapy after percutaneous coronary intervention in patients with type 2 diabetes mellitus
por: Liu, Mao, et al.
Publicado: (2018)

Antiplatelets/enoxaparin-sodium: Major bleeding: case report
Publicado: (2020)

Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding
por: Carlin, Neal, et al.
Publicado: (2017)

Dual antiplatelet therapy with ticagrelor may increase the risk of all bleeding events in patients with minor strokes or high risk TIAs: a meta-analysis
por: Chen, Xi, et al.
Publicado: (2022)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients
por: Kandzari, David E., et al.
Publicado: (2020)

Risk of Postdischarge Bleeding From Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among US Black and White Adults
por: Heindl, Brittain, et al.
Publicado: (2022)

Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis
por: Han, Yan, et al.
Publicado: (2023)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
por: Jeger, Raban V., et al.
Publicado: (2019)

The use of dual antiplatelet therapy for ischemic cerebrovascular events
por: Mele, Francesco, et al.
Publicado: (2022)

Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls
por: Godier, Anne, et al.
Publicado: (2020)

Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study
por: Doble, Brett, et al.
Publicado: (2018)

In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry
por: Yashima, Fumiaki, et al.
Publicado: (2021)

Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
por: Bainey, Kevin R., et al.
Publicado: (2023)

Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation
por: Lüsebrink, Enzo, et al.
Publicado: (2019)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Clinical Evaluation of Role of Dual Antiplatelet Therapy on Bleeding after Dental Extraction
por: Babaji, Prashant, et al.
Publicado: (2018)

Risk of bleeding in patients with continued dual antiplatelet therapy during orthopedic surgery
por: Hu, San-Bao, et al.
Publicado: (2019)

Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease
por: Tung, Ying-Chang, et al.
Publicado: (2020)

Increased Risk for Developing Major Adverse Cardiovascular Events in Stented Chinese Patients Treated with Dual Antiplatelet Therapy after Concomitant Use of the Proton Pump Inhibitor
por: Zou, Jian-Jun, et al.
Publicado: (2014)

Impact of Clopidogrel Stop Interval on Major Adverse Bleeding Events in Cardiac Surgery
por: Huo, Bright, et al.
Publicado: (2021)

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
por: Abergel, Eitan, et al.
Publicado: (2010)

BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding
por: Pan, ChangE, et al.
Publicado: (2012)

Patient perspectives of nuisance bleeding and adherence to dual antiplatelet therapy: a qualitative study
por: Pithara, Christalla, et al.
Publicado: (2020)

Early Dual-Antiplatelet Therapy at the Emergency Department Is Associated with Lower In-Hospital Major Adverse Cardiac Event Risk among Patients with Non-ST-Elevation Myocardial Infarction
por: Yang, Jen-Han, et al.
Publicado: (2021)

Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents
por: Yoshikawa, Yusuke, et al.
Publicado: (2021)

Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke
por: Hilkens, Nina A., et al.
Publicado: (2018)

Continue or Discontinue Dual Antiplatelet Therapy in Major Surgical or Endoscopic Procedures
por: Cheon, Young Koog
Publicado: (2013)

A randomized controlled trial of a physiology‐guided percutaneous coronary intervention optimization strategy: Rationale and design of the TARGET FFR study
por: Collison, Damien, et al.
Publicado: (2020)

CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention
por: Stys, Tomasz P., et al.
Publicado: (2021)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review
por: Tsigkas, Grigorios, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bs6dnjdhrhqrjgh090ki2aarko